Blockchain Registration Transaction Record

Quantum BioPharma Tackles MS and Alcohol Impairment with Novel Pipeline

Quantum BioPharma (QNTM) advances Lucid-MS for multiple sclerosis and unbuzzd for alcohol metabolism. Learn how these novel therapies target brain disorders affecting millions.

This news matters because multiple sclerosis affects nearly 3 million people worldwide, and current treatments often fail to repair nerve damage or prevent disability progression. Quantum BioPharma's Lucid-MS could offer a game-changing approach by promoting remyelination, potentially improving quality of life for millions. Additionally, the unbuzzd supplement addresses the widespread issue of alcohol hangover and intoxication, offering a science-backed solution for consumers. Together, these developments highlight a company targeting both chronic neurological disease and acute brain health, with implications for patients, investors, and public health.